Original Research and the Latest News

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

by | January 16, 2026 | New Technology, Probability of Success | 0 Comments

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

by | November 9, 2025 | New Technology, Probability of Success | 0 Comments

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

by | October 26, 2025 | Business, Data Analytics, Industry Trends, Market Scan, New Technology, Probability of Success | 0 Comments

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

Recent Tweets

Ozmosi Follow

BioPharma/Biotech Intel. Daily $XBI $XPH Market Movers Database: https://t.co/IBOqbSoYuc Clinical trial tools: https://t.co/A77u9Q84Dc https://t.co/AQERg9nHrb

OzmosiHealth
ozmosihealth Ozmosi @ozmosihealth ·
14h

$SIBN

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

More Info: https://pryzm.ozmosi.com/product/21260

Reply on Twitter 2104678413252653413 Retweet on Twitter 2104678413252653413 Like on Twitter 2104678413252653413 Twitter 2104678413252653413
ozmosihealth Ozmosi @ozmosihealth ·
14h

$REPL

Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1

More Info: https://pryzm.ozmosi.com/product/32432

Reply on Twitter 2104678410576617914 Retweet on Twitter 2104678410576617914 Like on Twitter 2104678410576617914 Twitter 2104678410576617914
ozmosihealth Ozmosi @ozmosihealth ·
21h

$PALI -1.02% today

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

More Info: https://pryzm.ozmosi.com/product/26086

Reply on Twitter 2104572862015455666 Retweet on Twitter 2104572862015455666 Like on Twitter 2104572862015455666 Twitter 2104572862015455666
ozmosihealth Ozmosi @ozmosihealth ·
21h

$OGN -0.04% today

Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older

More Info: https://pryzm.ozmosi.com/product/19085

Reply on Twitter 2104572859125531107 Retweet on Twitter 2104572859125531107 Like on Twitter 2104572859125531107 Twitter 2104572859125531107
Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

Get in Touch

info@ozmosi.com
(732) 701-7807

600 Warren Ave,
Spring Lake, NJ 07762